Voltage-gated K+ channels are associated with cell proliferation and cell cycle of ovarian cancer cell

Weng, Zhanping; Pan, Xiaoyu; Cui, Na; Wang, Shenglan; Wang, Bo

doi:10.1016/j.ygyno.2006.08.033

Cited by 30 publications

(23 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Glibenclamide was the first second-generation sulfonylurea drug, and it functions by targeting sulfonylurea receptors (SURs). To date, a number of studies have indicated that glibenclamide can inhibit the growth of various types of cancer (51)(52)(53)(54); however, the antitumor mechanisms have not been fully elucidated. In recent years, certain studies have focused on potassium (K + ) channels, which are involved in physiological cellular functions, including insulin release, cell proliferation, and apoptosis.…”

Section: Selection Comparability Outcome ----------------------------mentioning

confidence: 99%

Metformin use and its effect on gastric cancer in patients with type 2 diabetes: A systematic review of observational studies

Zhang

Gao

et al. 2017

Oncol Lett

View full text Add to dashboard Cite

Abstract. Increasing evidence suggests that metformin use is associated with a decreased risk of cancer. The traditional therapies for gastric cancer (GC) are gastrectomy and chemoradiotherapy; however, these therapies may cause certain adverse effects, which affect a patient's quality of life, and the overall survival rate is low. At present, little is known about whether the use of metformin decreases the risk of GC in patients with type 2 diabetes. Therefore, in the present study, a systematic review was performed to analyze the effect of metformin on GC. A literature search was conducted in PubMed, EMBASE, and the Cochrane Library databases for articles published up to June 30th, 2016. The studies that evaluated GC patients treated with metformin and compared them with GC patients treated with other antidiabetic drugs were reviewed. Eligible studies were evaluated using the Newcastle-Ottawa Scale. Adjusted hazard ratio and 95% confidence intervals were determined to evaluate the effect of metformin on GC. From the 422 articles evaluated, 5 studies involving a total of 1,804,479 patients met the inclusion criteria and were qualitatively analyzed. The quality of all selected articles was classified as moderate. These studies reported that the long-term use of metformin was associated with a lower risk of GC compared with the lack of use of metformin or the use of other hypoglycemic drugs. In GC patients with diabetes who were subjected to gastrectomy, the cumulative use of metformin reduced the rates of disease recurrence and of all-cause and cancer-specific mortality. Despite the limited number of studies on this subject, currently available evidence indicates that metformin is associated with a decreased risk of GC and improves survival in patients with type 2 diabetes. However, more well-designed trials are required to elucidate this association.

show abstract

Section: Selection Comparability Outcome ----------------------------mentioning

confidence: 99%

Metformin use and its effect on gastric cancer in patients with type 2 diabetes: A systematic review of observational studies

Zhang

Gao

et al. 2017

Oncol Lett

View full text Add to dashboard Cite

show abstract

“…For example, breast cancer cells (and probably many others) hyperpolarize during their passage through G0/G1 and into S phase by an increase in the potassium conductance of the membrane [18]. Inhibitors of voltage-gated potassium channels are therefore inhibitors of cell cycle progression in many cell culture models, like prostate [19,20], breast [21,22], colon [23,24] oral squamous [25,26], uterine [27], gastric [28], ovarian cancer [29] or gliomas [30]. In theory, all these tumor types would be susceptible to treatment with blockers of the particular respective potassium channel.…”

Section: Key Termsmentioning

confidence: 99%

“…Such an effect has been observed with treatment with nitric oxide donors [122] and dexamethasone [123]; in both cases, a concomitant increased K Ca 1.1 activity has been reported. In fact, the channel activator NS-1619 co-infusion with temozolomide and trastuzumab resulted in enhanced drug delivery to brain tumor cells [124] future science group on proliferation, pharmacological inhibition of the channel led to conflicting results probably depending on tumor type; in some cases, it impaired proliferation [125,126] but in others it had no effect [29,127,128].…”

Section: K Ca Channelsmentioning

confidence: 99%

K ⁺ Channels as Therapeutic Targets in Oncology

Stühmer

Pardo

2010

Future Med. Chem.

View full text Add to dashboard Cite

Ion channels are involved in a variety of tumors. In particular, potassium channels are expressed abnormally in many cancer types, where their pharmacologic manipulation impairs tumor progression. Since this group of molecules has been successfully targeted for decades in other therapeutic areas, there is a significant body of knowledge on the pharmacology of potassium channels. Several groups of potassium channels with defined molecular identities have been proposed as candidates for therapeutic intervention. The strategies put forward range from classical small molecule blockade to gene therapy approaches, and include the use of potassium channels as targets for adjuvant therapy. We will discuss the reasons for these proposals and explore possible future developments.

show abstract

“…Altered expression of a diversity of K + channels in human breast cancer cells, in human astrocytomas and glioblastomas, and in human ovarian cells including SKOV-3 have been documented in distinct cell models 11, 12 . Although ion channel activation through purinergic receptor stimulation is a well-known phenomenon, its role in cancer has not been thoroughly analyzed.…”

Section: Introductionmentioning

confidence: 99%

Kca3.1 Activation Via P2y2 Purinergic Receptors Promotes Human Ovarian Cancer Cell (Skov-3) Migration

Robles-Martínez

Garay

Martel-Gallegos

et al. 2017

Sci Rep

View full text Add to dashboard Cite

Disorders in cell signaling mediated by ATP or histamine, activating specific membrane receptors, have been frequently associated with tumorigenesis. Among the elements of response to purinergic (and histaminergic) signaling, ion channel activation controls essential cellular processes in cancer, such as cell proliferation, motility, and death. Here, we studied the effects that ATP had on electrical properties of human ovarian adenocarcinoma cells named SKOV-3. ATP caused increase in intracellular Ca2+ concentration ([Ca2+]i) and, concurrently, it evoked a complex electrical response with a conspicuous outward component. This current was generated through P2Y2 receptor activation and opening of K+ channels, KCa3.1, as indicated by electrophysiological and pharmacological analysis, as well as by immunodetection and specific silencing of P2Y2 or KCa3.1 gene by esiRNA transfection. Low µM ATP concentration increased SKOV-3 cell migration, which was strongly inhibited by KCa3.1 channel blockers and by esiRNA-generated P2Y2 or KCa3.1 downregulation. Finally, in human ovarian tumors, the P2Y2 and KCa3.1 proteins are expressed and co-localized in neoplastic cells. Thus, stimulation of P2Y2 receptors expressed in SKOV-3 cells promotes motility through KCa3.1 activation. Since P2Y2 and KCa3.1 are co-expressed in primary tumors, our findings suggest that they may play a role in cancer progression.

show abstract

Voltage-gated K+ channels are associated with cell proliferation and cell cycle of ovarian cancer cell

Cited by 30 publications

References 23 publications

Metformin use and its effect on gastric cancer in patients with type 2 diabetes: A systematic review of observational studies

Metformin use and its effect on gastric cancer in patients with type 2 diabetes: A systematic review of observational studies

K ⁺ Channels as Therapeutic Targets in Oncology

Kca3.1 Activation Via P2y2 Purinergic Receptors Promotes Human Ovarian Cancer Cell (Skov-3) Migration

Contact Info

Product

Resources

About

Voltage-gated K+ channels are associated with cell proliferation and cell cycle of ovarian cancer cell

Cited by 30 publications

References 23 publications

Metformin use and its effect on gastric cancer in patients with type 2 diabetes: A systematic review of observational studies

Metformin use and its effect on gastric cancer in patients with type 2 diabetes: A systematic review of observational studies

K + Channels as Therapeutic Targets in Oncology

Kca3.1 Activation Via P2y2 Purinergic Receptors Promotes Human Ovarian Cancer Cell (Skov-3) Migration

Contact Info

Product

Resources

About

K ⁺ Channels as Therapeutic Targets in Oncology